Metabolic Impact of Sex Hormones on Obesity

By: Lynda M. Brown, Lana Gent, Kathryn Davis, and Deborah J. Clegg

Abstract:
Obesity and its associated health disorders and costs are increasing. Men and postmenopausal women have greater risk of developing complications of obesity than younger women. Within the brain, the hypothalamus is an important regulator of energy homeostasis. Two of its sub-areas, the ventrolateral portion of the ventral medial nucleus (VL VMN) and the arcuate (ARC) respond to hormones and other signals to control energy intake and expenditure. When large lesions are made in the hypothalamus which includes both the VL VMN and the ARC, animals eat more, have reduced energy expenditure, and become obese. The ARC and the VL VMN, in addition to other regions in the hypothalamus, have been demonstrated to contain estrogen receptors. There are two estrogen receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). We and others have previously demonstrated that activation of ERα by estrogens reduces food intake and increases body weight. This review focuses on the relative contribution of activation of ERα by estrogens in the ARC and the VL VMN in the regulation of food intake and body weight. Additionally, estrogen receptors have been found in many peripheral tissues including adipose tissue. Estrogens are thought to have direct effects on adipose tissue and estrogens may provide anti-inflammatory properties both in the periphery and the in the central nervous system (CNS) which may protect women from diseases associated with inflammation. Understanding the mechanisms by which estrogens regulate body weight and inflammation will assist in determining potential therapeutic agents for menopausal women to decrease the propensity of diseases associated with obesity.

Article:
INTRODUCTION
Obesity, resulting from an imbalance between energy intake and expenditure, is now recognized as a serious and global health problem (Steinbaum, 2004; Berthoud and Morrison, 2008). More than 300 million adults worldwide are obese, and in the United States, over 30% of the population are considered obese and 60% are overweight (Wang et al., 2008). Obese individuals are at an increased risk for developing type II diabetes, hypertension, coronary heart disease and stroke. In the United States obesity is associated with 300,000 premature deaths every year (Allison et al., 1999). The past decade has been attempting to identifying key hormones and other signals that influence body weight.

Males and females differ in terms of how and where they store body fat, the hormones they secrete in proportion to their fat, and the way their brains respond to signals that regulate food

intake and body weight (Clegg et al., 2003; Clegg et al., 2006). The focus of this review is to discuss the potential role of estrogens as determinants mediating the sexual dimorphism in body weight regulation. In women, estrogens may be responsible for body weight homeostasis. Reductions in circulating estrogens, which occurs following ovariectomy (OVX) in experimental rodent models, results in increased body adiposity which can be ameliorated by exogenous estradiol-17β administration (Clegg et al., 2003; Clegg et al., 2006). In women, menopause is has been associated with increased in adiposity and shifts in body fat distribution, which can be altered by exogenous hormone replacement therapy (Samaras et al., 1999; Ryan et al., 2002).

HYPOTHALAMIC CONTROL OF BODY WEIGHT

In an effort to identify targets for therapeutic treatments to reduce food intake and body weight, obesity research has focused on central metabolic and hormonal pathways that control energy homeostasis (Obici, 2009). The hypothalamus is one area within the CNS that has received attention as a region in the brain that controls food intake, energy expenditure and body weight homeostasis. Since the 1930's, several thousand reports have been published investigating the potential role of various hypothalamic nuclei in the regulation of food intake and body weight (York and Bray, 1972; Bray et al., 1982; Bray, 1984). Early interest in the hypothalamus stemmed from findings that dramatic changes in food intake, body weight, and energy homeostasis could be produced by lesioning specific hypothalamic nuclei, such as the ventral medial hypothalamus (VMH) (Hetherington and Ranson, 1940; Rowland et al., 1975; Louis-Sylvestre et al., 1980) or the lateral hypothalamic area (LH) (Anand and Brobeck, 1951; Danguir and Nicolaidis, 1980; Milam et al., 1980). More recently, areas in the hypothalamus such as the ventral medial nucleus (VMN) and arcuate (ARC) nucleus (among others) have been identified as targets for hormonal and neuropeptide signals that can produce marked in energy homeostasis.

ESTROGEN RECEPTORS AND BODY WEIGHT REGULATION

The classical nuclear estrogen receptor (ER) was cloned in 1985 (Green et al., 1986) and renamed estrogen receptor alpha (ERα) when a second nuclear estrogen receptor (estrogen receptor beta (ERβ)), was discovered 10 years later (Kuiper et al., 1996). Both ERs are also expressed in the brain (Simerly et al., 1990; Kuiper et al., 1996; Shughrue et al., 1997; Simonian and Herbison, 1997; Voisin et al., 1997; Osterlund et al., 1998; Mitra et al., 2003; Merchenthaler et al., 2004). Stimulation of ERs engages both genomic and non-genomic events that may mediate distinct functions of estrogens. Little is known about the critical intracellular signals that mediate the anorexigenic effects of estrogens. Genomic activation of ERs results from estrogens binding to estrogen response elements (EREs) in promoter regions of target genes (Pappas et al., 1995; Razandi et al., 1999). Additionally, estrogens can also initiate rapid signaling events within minutes via non-genomic mechanisms (Kelly and Levin, 2001). ERs in the plasma membrane are able to activate the MAP-kinase cascade and PI3K pathway, causing a rise in intracellular calcium (Balthazart et al., 2001; Sutter-Dub, 2002). ERs also activate protein kinase B (PKB/Akt) in neurons (Singh, 2001; Ivanova et al., 2002; Wilson et al., 2002). The PI3K/Akt cascade mediates a variety of estrogens' central actions, including neuronal excitability, neuroprotection, reductions in inflammation, and neurite outgrowth (Vasudevan and Pfaff, 2008), and potentially body weight regulation. Estrogens' activation of ERs results in a range of biological effects which will be described in more detail below.

Male and female mice with a targeted deletion in the ERα gene (ERαKO) have increased adiposity (Heine et al,. 2000). The cause of the obesity is unclear; however, overeating does not appear to be essential (Shughrue et al., 1997; Shughrue et al., 1997; Heine et al., 2000; Ohlsson et al., 2000; Vidal et al., 2000; Geary et al., 2001), and the increased adiposity in ERαKO mice is attributed primarily to decreased energy expenditure (Heine et al., 2000; Ohlsson et al., 2000). While estradiol-17β replacement prevents OVX wildtype mice from developing hyperphagia and obesity, such protective effects are blocked in OVX ERαKO mice (Geary et al., 2001).

Additionally, both estrogen receptors (ERs) are expressed in peripheral tissues, such as adipose tissue, where they may influence adiposity and inflammation. Further supporting a role for ERα in the regulation of body weight, are the findings that increased visceral adiposity has been associated with the Xbal polymorphism of the human ERα gene, in which guanidine is substituted for adenine in exon one (Speer et al., 2001; Yamada et al., 2002; Okura et al., 2003). A study of over two thousand Japanese women reported that there was increased fat mass and waist-hip ratios (an index of visceral adiposity) in pre-menopausal women that had the polymorphism compared to the control cohort of women with the normal genotype (Yamada et al., 2002; Okura et al., 2003; Okura et al., 2003). The polymorphism did not affect adiposity in postmenopausal women or in men. Thus, polymorphisms of the human ERα gene may impair estrogen signaling and lead to increased visceral adiposity and its attendant health risks.

CNS ERs AND BODY WEIGHT REGULATION
Due to the findings that targeted deletion in the ERα gene (ERαKO) have increased adiposity (Heine et al., 2000), ERα may be important in the regulation of body weight. ERα is ubiquitously expressed in rodent brains, but the physiologically relevant sites of ERα in the regulation of food intake and energy expenditure have not been identified. ERα is expressed in the ventrolateral portion of the VMN, the ARC, the medial preoptic area (MPOA), and the paraventricular nuclei (PVN) (Simerly et al., 1990; Simonian and Herbison, 1997; Voisin et al., 1997; Osterlund et al., 1998; Wilkinson et al., 2002; Shima et al., 2003; Merchenthaler et al., 2004). ERβ is found in the same hypothalamic nuclei as ERα, but ERβ expression is significantly reduced relative to ERα.

In earlier attempts to determine the effects of estrogens on food intake and body weight in hypothalamic regions, intranuclear microinjections of estradiol benzoate were performed (Wade and Zucker 1970). However, due to the difficulty in precisely placing cannulae or producing lesions in small but complex hypothalamic regions, findings obtained from these studies are somewhat controversial. For example, earlier studies showed that estradiol-17β implanted in the PVN decreases food intake and body weight in OVX rats (Butera and Beikirch, 1989) in the absence of any signs of peripheral estrogenic stimulation. Additionally, the anorexigenic effects of subcutaneous estradiol-17β are blunted in rats with PVN lesions (Butera et al., 1992). However, the subsequent studies failed to reproduce these phenotypes in rats with PVN implants (Hrupka et al., 2002). Effects of estrogen in the MPOA are also controversial, with only one report showing an anorexigenic response of estradiol-17β (Dagnault and Richard, 1997), whereas several other groups showed that estradiol-17β implanted in this nucleus has no effect on feeding (Butera and Beikirch, 1989). The ARC and VMH are nearby structures in the ventral hypothalamus. Earlier microinjection studies may not have been able to rigorously distinguish these two regions, and therefore failed to provide consistent results (Butera and Beikirch, 1989). However, we have reported that site-specific reductions of ERα in the VL VMN result in

increased adiposity, no change in food intake, and suppression of energy expenditure, implicating VL VMN ERα in energy homeostasis (Musatov et al., 2007). Additionally, the hindbrain (caudal NTS) might be another site of estrogens' regulation of food intake due to the recent findings of Thammacharoen where they placed an estradiol-containing haemostatic cloth which decreased food intake in OVX rats (Thammacharoen et al., 2008).

Following OVX, the oft-observed consequence is that a rat becomes transiently hyperphagic and gains weight, mainly as fat (Wade, 1972; Drewett, 1973; Leshner and Collier, 1973; Blaustein and Wade, 1976; Wade and Gray, 1979; Wade et al., 1985; Kemnitz et al., 1989; Wallen et al., 2001). However, an important but often forgotten aspect of OVX is that there is not an obligatory increase of food intake. OVX rats that are pair-fed to estradiol-17β-treated rats, however, increase body weight, gaining as much as *ad libitum*-fed OVX rats (Mueller and Hsiao, 1980). Additionally, if a female rat is fattened prior to removal of the ovaries, she simply remains fat after the operation without the necessity of overeating; i.e., the OVX (and presumably lack of estrogens) dictated that the rat carry more fat, but did not dictate that the rat become hyperphagic (Bartness and Waldbillig, 1984).

ESTROGENS INTERACT WITH LEPTIN

First described in 1994 (Zhang et al., 1994), leptin has proven to be a key metabolic protein with actions throughout the body. Leptin provides a powerful catabolic signal to the brain, resulting in inhibition of food intake and increasing energy expenditure (Ahima et al., 1999; Elias et al., 1999; Elmquist et al., 1999; Schwartz et al., 2000; Woods et al., 2000; Morton et al., 2003; Seeley and Woods, 2003; Balthasar et al., 2004; Schwartz and Porte, 2005). Leptin is secreted from adipose tissue in direct proportion to fat content, and it crosses the blood-brain barrier to interact with leptin receptors in the hypothalamus and brainstem (Tartaglia et al., 1995; Ahima et al., 1996; Seeley et al., 1996; Ahima et al., 1999; Elias et al., 1999; Morton et al., 2003; Schwartz and Porte, 2005). Although there are several splice variants of the leptin receptor, the long form (termed leprb) is the critical variant for regulating energy balance (Chen et al., 1996). Leprb are localized in several brain areas including the VMN and the ARC, and leprb are colocalized with several neuropeptides believed to be involved in controlling food intake and reproduction (Van Dijk et al., 1996; Elmquist et al., 1997; Elmquist et al., 1998). Leptin has the ability to activate or inhibit hypothalamic neurons (Elmquist et al., 1998; Elmquist et al., 1998; Elmquist et al., 1998). Thus, leptin is ideally situated to link metabolic status and brain function. It has been reported that leprb expression in the ARC is co-localized with ERα (Diano et al., 1998), and estrogens have been reported to regulate the expression of leprb mRNA in the ARC (Bennett et al., 1999), possibly via an ERE on the leptin receptor gene (Lindell et al., 2001). The extensive hypothalamic co-localization of these two receptors suggests a closely coupled interaction between these peripheral signals in the regulation of energy homeostasis.

Leptin levels are higher in females, even before puberty, compared with males, and these levels are independent of differences in body composition (Shimizu et al., 1997; Demerath et al., 1999; Wu-Peng et al., 1999). After puberty, estrogens and testosterone further modulate leptin synthesis and secretion via sex steroid receptor-dependent transcriptional mechanisms (Machinal et al., 1999).

Estrogens may be modulators of leptin's catabolic action in the brain. Higher levels of estrogens have been associated with increased leptin sensitivity (Ainslie et al., 2001; Clegg et al., 2003; Clegg et al., 2006). Although circulating leptin levels do not change appreciably during the estrous cycle, ARC leprb expression is highest during estrous and metestrous and is inversely correlated with neuropeptide Y (NPY) mRNA expression (Bennett et al., 1999). OVX lowers sensitivity to central leptin when compared to intact females, and this can be restored by estradiol-17β replacement (Clegg et al., 2006). Analogously, exogenous estradiol-17β administration to male rats will increase sensitivity to central leptin (Clegg et al., 2006). The differences in leptin sensitivity caused by the presence or absence of estrogens may occur downstream of leprb transcription and translation. Additionally, females have greater c-Fos (a marker of neuronal activaton) and pSTAT3 (a marker of leptin receptor activation) immunoreactivity in the ARC than males following intra-third ventricular leptin (unpublished data), which suggests that enhanced leptin sensitivity. Therefore, there may be a threshold for estrogens required to enhance the central sensitivity to leptin.

It should be noted that OVX greatly reduces, but does not eliminate the most physiologically active estrogen, estradiol-17β, since adrenal androgens and other steroids can be aromatized to estrogens in fat and other tissue. Additionally, there is a second form of estradiol, estradiol-17α, which can be synthesized in peripheral tissue (Finkelstein et al., 1981) and in some brain areas (MacLusky et al., 1994) from aromatization of epitestosterone by cytochrome P450 aromatase. Recent reports demonstrated that estradiol-17α has binding affinity for the ERα receptor and that levels increase in the hypothalamus of OVX females (Toran-Allerand, 2005; Toran-Allerand et al., 2005). Peripheral and central administration estradiol-17α decreases food intake and body weight of OVX rats (Donohoe et al., 1984; Butera et al., 1990). These findings suggest that estradiol-17α may modulate estrogen regulation of energy balance and, further, that even following OVX, estradiol-17α may activate ERα.

Leptin resistance may also occur in other states such as pregnancy (Ladyman and Grattan, 2005). These authors demonstrated that pregnant rats treated with leptin had impaired activation of pSTAT3 and reduced leprb mRNA in the VMH when compared to non-pregnant females. However, there were no changes in leptin activation of pSTAT3 in the ARC of pregnant females, nor were there changes in leprb in pregnant versus non-pregnant females. Pregnancy is a state of relative deficiency of estrogens, and these data may support the idea that low levels of estrogens is associated with reduced leptin sensitivity.

ESTROGEN INTERACTS WITH THE MELANOCORTIN SYSTEM
The ARC has been well-investigated with regard to central leptin action (Woods and Seeley, 2000; Williams et al., 2001). Leprb is expressed by two populations of ARC neurons, those expressing proopiomelanocortin (POMC) (Cheung et al., 1997; Thornton et al., 1997) and those expressing NPY and agouti-related peptide (NPY/AgRP neurons) (Baskin et al., 1999). NPY is an effective anabolic peptide. Central administration of NPY potently increases food intake and decreases energy expenditure and fat oxidation (Chavez et al., 1995; Levin, 1999; Cone et al., 2001; Herzog, 2003). ARC neurons co-express NPY mRNA and leprb protein. Leptin administration decreases, while lack of leptin or leptin signaling increases, NPY (and AgRP) mRNA, demonstrating that leptin is a critical determinant of ARC NPY functioning (Baskin et al., 1999). POMC neurons secrete the catabolic melanocortin neuropeptide, α melanocyte

stimulating hormone (αMSH), which acts in the PVN and lateral hypothalamus on melanocortin 3 and melanocortin 4 (MC3/MC4) receptors to produce a profound catabolic effect by reducing food intake and increasing energy expenditure (Elmquist et al., 1998; Elias et al., 1999; Elmquist et al., 1999; Elias et al., 2000). If administered chronically, MC3/4 agonists reduce body weight and adiposity (Pierroz et al., 2002). Leptin stimulates POMC neurons to synthesize and release αMSH (Seeley et al., 1997; Korner et al., 1999). AgRP is an antagonist at MC3/MC4 receptors, and its administration increases food intake. Hence, within the ARC, leptin elicits a powerful catabolic affect by activating αMSH and simultaneously inhibiting anabolic NPY/AgRP production and release. This produces reduced feeding and increased energy expenditure (Elmquist et al., 1999). Recently, NPY neurons in the ARC where not found to co-express ERα (Olofsson et al., 2009); whereas we and others have found that POMC neurons do co-express ERα (Simonian et al., 1999). Because the leprb gene contains an ERE (Lindell et al., 2001), this provides a critical potential mechanistic link between estrogens' activity and that of leptin on ARC POMC neurons.

A wealth of data support a role for NPY in the regulation of food intake and body weight, e.g., (Herzog, 2003). Consistent with a role of estrogens in the regulation of food intake and body weight, estrogen suppresses NPY release. OVX increases and estradiol-17β treatment decreases levels of NPY mRNA in the ARC (Baskin et al., 1995; Ainslie et al., 2001). Additionally, food deprivation increases ARC NPY mRNA levels less in estradiol-17β treated OVX rats than in vehicle-treated OVX rats (Baskin et al., 1995). Lastly, chronic estradiol-17β treatment decreases NPY levels and NPY release in the PVN (Bonavera et al., 1994).

POMC levels are also responsive to gonadal steroids. POMC mRNA levels fluctuate over the course of the estrous cycle, with the most dramatic changes on the day of proestrus (Wise et al., 1990; Bohler et al., 1991; Korner et al., 1999; Slamberova et al., 2004). POMC neurons express ERα, and OVX decreases POMC mRNA, which is reversed by estradiol-17β replacement (Pelletier et al., 2007). Lower POMC levels are also observed in ERα knockout mice (Hirosawa et al., 2008). Estrogens activate POMC neurons partly via PI3K-mediated mechanisms (Qiu et al., 2003; Malyala et al., 2008). Estradiol-17β administration rapidly increases activity at incoming excitatory synapses onto POMC neurons, enhancing miniature excitatory postsynaptic current recorded from POMC-GFP neurons (Gao et al., 2007). These synaptic rearrangements in POMC neurons tightly parallel the effects of estrogens on food intake, energy expenditure and body weight (Gao et al., 2007). Collectively, these findings suggest that ERα in POMC neurons may contribute to energy homeostasis and the effects of estrogens.

ESTROGEN REGULATES ADIPOSITY
The accumulation of fat centrally (intra-abdominal/visceral adipose tissue) has emerged as a risk factor for the metabolic syndrome (Kannel et al., 1991; Lee et al., 2009). Estrogens promote the accumulation of subcutaneous fat (Krotkiewski et al., 1983); however, visceral fat varies inversely with levels of estrogens (Bouchard et al., 1993). The loss of estrogens with menopause is associated with an increase in intra-abdominal fat accrual (Poehlman et al., 1995; Lee et al., 2009). OVX rats gain fat, specifically visceral fat with no change of subcutaneous fat (Clegg et al., 2006). Furthermore, peripheral or central administration of estradiol-17β to OVX rats changes their body fat distribution to mirror that of intact females. Altering the sex hormone milieu in males with estradiol-17β administration increases subcutaneous fat deposition (Clegg et

al., 2006). An important implication from these findings is that estrogens may be critical determinates of body fat distribution.

Progesterone and androgen receptors (PR and AR) as well as ERs are expressed in adipose tissues (Crandall et al., 1998). Subcutaneous adipose tissue has higher concentrations of ERs and PR; however, visceral adipose tissue has higher concentrations of AR (Lu et al., 1998). Additionally, subcutaneous adipose tissue has few AR, and estrogens down-regulates AR expression in subcutaneous fat (Bjorntorp, 1997). Adipose tissue-specific AR knockout mice have increased intra-adipose estrogens, which leads to increased subcutaneous obesity and hyperleptinemia (Yu et al., 2008). The sexual dimorphism in adipose tissue distribution may partially explain the greater risk for the metabolic syndrome in men compared with premenopausal women.

ESTROGEN DECREASES INFLAMMATION
Obesity is now recognized as a global health problem as previously mentioned, and it may be a result of increased consumption of high fat (HF) diets. Free fatty acids (FFAs), particularly saturated fatty acids, increase inflammation by activating toll-like receptor 4 (TLR4) (Shi et al., 2006). It is increasingly evident that chronic activation of pro-inflammatory pathways may be at least partly responsible for obesity-induced insulin resistance and diabetes (Kahn and Flier, 2000; Wellen and Hotamisligil, 2003; Wellen and Hotamisligil, 2005). For example, the pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα), interleukin-6 (IL-6) and C-reactive protein are elevated in individuals with insulin resistance and diabetes (Shoelson et al., 2007; de Luca and Olefsky, 2008; Wang et al., 2008), and elevated in muscle and liver with HF diets (Shi et al., 2006). Suppression of pro-inflammatory responses represents a promising strategy to combat obesity and associated disorders. ERs are expressed in monocytes and macrophages, and estrogens activate these cells (Vegeto et al., 2001; Pozzi et al., 2006). Female rats and mice are relatively protected from HF-induced obesity, insulin resistance and inflammatory responses (Dhar et al., 2004; Gallou-Kabani et al., 2007; Payette et al., 2009). Recent studies have shown that estradiol-17β may play a role in reducing the inflammatory response in adipose, cardiovascular, and neural systems (Turgeon et al., 2006; (hisletti et al., 2005).

In vitro studies have demonstrated estradiol-17β -activated ERα decreases the number of pro-inflammatory cytokines (Vegeto et al., 2001; Vegeto et al., 2003). The anti-inflammatory properties of estradiol-17β can be partially explained by the ability of ERs to act as transcriptional repressors by inhibiting the activity of nuclear factor kappa B (NFκB) through protein-protein interactions between agonist-bound ERs and activated NFκB subunits (Stein and Yang, 1995; Ghisletti et al., 2005; Kalaitzidis and Gilmore, 2005). Estrogens' inhibitory effect on NFκB function is not fully understood and may be target selective (Harris et al., 2003; Chadwick et al., 2005; Kalaitzidis and Gilmore, 2005; Wise et al., 2009). The PI3K pathway is also implicated in the anti-inflammatory effects of estrogens. For example, estradiol-17β blocks LPS-induced NFκB nuclear translocation in macrophages, an effect that involves the activation of PI3K (Ghisletti et al., 2005). Similarly, estradiol-17β decreases vascular leukocyte accumulation after an ischemia-reperfusion injury (Simoncini et al., 2000). These effects are blocked by PI3K inhibitors (Simoncini et al., 2000).

CONCLUSION

When women enter menopause, they have a dramatically increased risk for developing obesity, type II diabetes and the metabolic syndrome. Hormone replacement therapy (HRT) could be seen as a way to reduce these risks and, in fact, recent data suggest that pharmacological estrogens can reverse the progression of metabolic diseases. However, due to ubiquitous expression of ERs, especially in peripheral tissues, and to complex intracellular events coupled to ERs ("genomic" and "non-genomic" actions), the metabolic benefits provided by HRT are often associated with increased risk of heart disease and breast cancer. Obviously, one solution to this dilemma would be to target only the ERs involved in energy balance and to develop estrogen-like drugs that only initiate intracellular events that produce metabolic benefits without unwanted side effects. Therefore, future research should focus on identifying the critical brain sites where ERs regulate body weight homeostasis and delineate the intracellular signaling pathways that are required for estrogens' actions. Additionally, understanding the functional role of ERs in the periphery may reveal new pharmacological targets for the beneficial actions of therapeutic estrogens without the deleterious side effects.

REFERENCES

Ahima, R.S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Flier-Maratos, E., Flier, J.S., 1996. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250–252.

Ahima, R.S., Kelly, J., Elmquist, J.K., Flier, J.S., 1999. Distinct physiologic and neuronal responses to decreased leptin and mild hyperleptinemia. Endocrinology 140, 4923–4931.

Ainslie, D.A., Morris, M.J., Wittert, G., Turnbull, H., Proietto, J., Thorburn, A.W., 2001. Estrogen deficiency causes central leptin insensitivity and increased hypothalamic neuropeptide Y. Int. J. Obes. Relat. Metab. Disord. 25, 1680–1688.

Allison, D.B., Fontaine, K.R., Manson, J.E., Stevens, J., VanItallie, T.B., 1999. Annual deaths attributable to obesity in the United States. JAMA 282, 1530–1538.

Anand, B.K., Brobeck, J.R., 1951. Hypothalamic control of food intake in rats and cats. Yale J. Biol. Med. 24, 123–140.

Balthasar, N., Coppari, R., McMinn, J., Liu, S.M., Lee, C.E., Tang, V., Kenny, C.D., McGovern, R.A., Chua Jr., S.C., Elmquist, J.K., Lowell, B.B., 2004. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 42, 983–991.

Balthazart, J., Baillien, M., Ball, G.F., 2001. Phosphorylation processes mediate rapid changes of brain aromatase activity. J. Steroid Biochem. Mol. Biol. 79, 261–277.

Bartness, T.J., Waldbillig, R.J., 1984. Dietary self-selection in intact, ovariectomized, and estradiol-treated female rats. Behav. Neurosci. 98, 125–137.

Baskin, D.G., Norwood, B.J., Schwartz, M.W., Koerker, D.J., 1995. Estradiol inhibits the increase of hypothalamic neuropeptide Y messenger ribonucleic acid expression induced by weight loss in ovariectomized rats. Endocrinology 136, 5547–5554.

Baskin, D.G., Breininger, J.F., Schwartz, M.W., 1999. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 48, 828–833.

Bennett, P.A., Lindell, K., Wilson, C., Carlsson, L.M., Carlsson, B., Robinson, I.C., 1999. Cyclical variations in the abundance of leptin receptors, but not in circulating leptin, correlate with NPY expression during the oestrous cycle. Neuroendocrinology 69, 417–423.

Berthoud, H.R., Morrison, C., 2008. The brain, appetite, and obesity. Annu. Rev. Psychol. 59, 55–92.

Bjorntorp, P., 1997. Hormonal control of regional fat distribution. Hum. Reprod. 12 (Suppl 1), 21–25.

Blaustein, J.D., Wade, G.N., 1976. Ovarian influences on the meal patterns of female rats. Physiol. Behav. 17, 201–208.

Bohler Jr., H.C., Tracer, H., Merriam, G.R., Petersen, S.L., 1991. Changes in proopiomelanocortin messenger ribonucleic acid levels in the rostral periarcuate region of the female rat during the estrous cycle. Endocrinology 128, 1265–1269.

Bonavera, J.J., Dube, M.G., Kalra, P.S., Kalra, S.P., 1994. Anorectic effects of estrogen may be mediated by decreased neuropeptide-Y release in the hypothalamic paraventricular nucleus. Endocrinology 134, 2367–2370.

Bouchard, C., Despres, J.P., Mauriege, P., 1993. Genetic and nongenetic determinants of regional fat distribution. Endocr. Rev. 14, 72–93.

Bray, G.A., 1984. Hypothalamic and genetic obesity: an appraisal of the autonomic hypothesis and the endocrine hypothesis. Int. J. Obes. 8 (supplement 1), 119–137.

Bray, G.A., Sclafani, A., Novin, D., 1982. Obesity-inducing hypothalamic knife cuts: effects on lipolysis and blood insulin levels. Am. J. Physiol. 243, R445–R449.

Butera, P.C., Beikirch, R.J., 1989. Central implants of diluted estradiol: independent effects on ingestive and reproductive behaviors of ovariectomized rats Brain Res. 491, 266–273.

Butera, P.C., Beikirch, R.J., Willard, D.M., 1990. Changes in ingestive behaviors and body weight following intracranial application of 17 alpha-estradiol. Physiol. Behav. 47, 1291–1293.

Butera, P.C., Willard, D.M., Raymond, S.A., 1992. Effects of PVN lesions on the responsiveness of female rats to estradiol. Brain Res. 576, 304–310.

Chadwick, C.C., Chippari, S., Matelan, E., Borges-Marcucci, L., Eckert, A.M., Keith Jr., J.C., Albert, L.M., Leathurby, Y., Harris, H.A., Bhat, R.A., Ashwell, M., Trybulski, E., Winneker, R.C., Adelman, S.J., Steffan, R.J., Harnish, D.C., 2005. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 102, 2543–2548.

Chavez, M., van Dijk, G., Arkies, B.J., Woods, S.C., 1995. Third ventricular insulin infusion attenuates NPY-induced feeding at the level of the paraventricular nucleus. Obes. Res. 3, 335s.

Chen, H., Charlat, O., Tartaglia, L.A., Woolf, E.A., Weng, X., Ellis, S.J., Lakey, N.D., Culpepper, J., Moore, K.J., Breitbart, R.E., Duyk, G.M., Tepper, R.I., Morgenstern, J.P., 1996. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice Cell 84, 491–495.

Cheung, C.C., Clifton, D.K., Steiner, R.A., 1997. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 138, 4489–4492.

Clegg, D.J., Benoit, S.C., Barrera, J.G., Woods, S.C., 2003a. Estrogen mediates body fat distribution and brain sensitivity to adiposity signals. Diabetes 52 (supplement 1).

Clegg, D.J., Benoit, S.C., Fisher, M.E., Barrera, J.G., Seeley, R.J., Woods, S.C., 2003b. Sex hormones determine body fat distribution and sensitivity to adiposity signals. Appetite 40, 324.

Clegg, D.J., Riedy, C.A., Smith, K.A., Benoit, S.C., Woods, S.C., 2003c. Differential sensitivity to central leptin and insulin in male and female rats. Diabetes 52, 682–687.

Clegg, D.J., Brown, L.M., Woods, S.C., Benoit, S.C., 2006. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 55, 978–987.

Cone, R.D., Cowley, M.A., Butler, A.A., Fan, W., Marks, D.L., Low, M.J., 2001. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int. J. Obes. Relat. Metab. Disord. 25 (Suppl 5), S63–S67.

Crandall, D.L., Busler, D.E., Novak, T.J., Weber, R.V., Kral, J.G., 1998. Identification of estrogen receptor beta RNA in human breast and abdominal subcutaneous adipose tissue. Biochem. Biophys. Res. Commun. 248, 523–526.

Dagnault, A., Richard, D., 1997. Involvement of the medial preoptic area in the anorectic action of estrogens. Am. J. Physiol. 272, R311–R317.

Danguir, J., Nicolaidis, S., 1980. Cortical activity and sleep in the rat lateral hypothalamic syndrome. Brain Res. 185, 305–321.

de Luca, C., Olefsky, J.M., 2008. Inflammation and insulin resistance. FEBS Lett. 582, 97–105.

Demerath, E.W., Towne, B., Wisemandle, W., Blangero, J., Chumlea, W.C., Siervogel, R.M., 1999. Serum leptin concentration, body composition, and gonadal hormones during puberty. Int. J. Obes. Relat. Metab. Disord. 23, 678–685.

Dhar, M.S., Sommardahl, C.S., Kirkland, T., Nelson, S., Donnell, R., Johnson, D.K., Castellani, L.W., 2004. Mice heterozygous for Atp10c, a putative amphipath, represent a novel model of obesity and type 2 diabetes. J. Nutr. 134, 799–805.

Diano, S., Kalra, S.P., Horvath, T.L., 1998. Leptin receptor immunoreactivity is associated with the Golgi apparatus of hypothalamic neurons and glial cells. J. Neuroendocrinol. 10, 647–650.

Donohoe, T.P., Stevens, R., Johnson, N.J., Barker, S., 1984. Effects of stereoisomers of estradiol on food intake, body weight and hoarding behavior in female rats. Physiol. Behav. 32, 589–592.

Drewett, R.F., 1973. Sexual behaviour and sexual motivation in the female rat. Nature 242, 476–477.

Elias, C.F., Aschkenasi, C., Lee, C., Kelly, J., Ahima, R.S., Bjorbaek, C., Flier, J.S., Saper, C.B., Elmquist, J.K., 1999. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 23, 775–786.

Elias, C.F., Kelly, J.F., Lee, C.E., Ahima, R.S., Drucker, D.J., Saper, C.B., Elmquist, J.K., 2000. Chemical characterization of leptin-activated neurons in the rat brain [In Process Citation]. J. Comp. Neurol. 423, 261–281.

Elmquist, J.K., Ahima, R.S., Maratos-Flier, E., Flier, J.S., Saper, C.B., 1997. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology 138, 839–842.

Elmquist, J.K., Ahima, R.S., Elias, C.F., Flier, J.S., Saper, C.B., 1998a. Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. Proc. Natl. Acad. Sci. U. S. A. 95, 741–746.

Elmquist, J.K., Bjorbaek, C., Ahima, R.S., Flier, J.S., Saper, C.B., 1998b. Distributions of leptin receptor mRNA isoforms in the rat brain. J. Comp. Neurol. 395, 535–547.

Elmquist, J.K., Maratos-Flier, E., Saper, C.B., Flier, J.S., 1998c. Unraveling the central nervous system pathways underlying responses to leptin. Nat. Neurosci. 1, 445–450.

Elmquist, J.K., Elias, C.F., Saper, C.B., 1999. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22, 221–232.

Finkelstein, M., Weidenfeld, J., Ne'eman, Y., Samuni, A., Mizrachi, Y., Ben-Uzilio, R., 1981. Comparative studies of the aromatization of testosterone and epitestosterone by human placental aromatase. Endocrinology 108, 943–947.

Gallou-Kabani, C., Vige, A., Gross, M.S., Boileau, C., Rabes, J.P., Fruchart-Najib, J., Jais, J.P., Junien, C., 2007. Resistance to high-fat diet in the female progeny of obese mice fed a control diet during the periconceptual, gestation, and lactation periods. Am. J. Physiol. Endocrinol. Metab. 292, E1095–E1100.

Gao, Q., Mezei, G., Nie, Y., Rao, Y., Choi, C.S., Bechmann, I., Leranth, C., Toran-Allerand, D., Priest, C.A., Roberts, J.L., Gao, X.B., Mobbs, C., Shulman, G.I., Diano, S., Horvath, T.L., 2007. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat. Med. 13, 89–94.

Geary, N., Asarian, L., Korach, K.S., Pfaff, D.W., Ogawa, S., 2001. Deficits in E2-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-alpha null mice. Endocrinology 142, 4751–4757.

Ghisletti, S., Meda, C., Maggi, A., Vegeto, E., 2005. 17beta-estradiol inhibits inflammatory gene expression by controllingNF-kappaB intracellular localization. Mol. Cell. Biol. 25, 2957–2968.

Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.M., Argos, P., Chambon, P., 1986. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320, 134–139.

Harris, H.A., Albert, L.M., Leathurby, Y., Malamas, M.S., Mewshaw, R.E., Miller, C.P., Kharode, Y.P., Marzolf, J., Komm, B.S., Winneker, R.C., Frail, D.E., Henderson, R.A., Zhu, Y., Keith Jr., J.C., 2003. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144, 4241–4249.

Heine, P.A., Taylor, J.A., Iwamoto, G.A., Lubahn, D.B., Cooke, P.S., 2000. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. U. S. A. 97, 12729–12734.

Herzog, H., 2003. Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur. J. Pharmacol. 480, 21–29.

Hetherington, R., Ranson, S., 1940. Hypothalamic lesions and adiposity in the rat. Anat. Rec. 78, 149–172.

Hirosawa, M., Minata, M., Harada, K.H., Hitomi, T., Krust, A., Koizumi, A., 2008. Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by leptin and insulin. Biochem. Biophys. Res. Commun. 371, 320–323.

Hrupka, B.J., Smith, G.P., Geary, N., 2002. Hypothalamic implants of dilute estradiol fail to reduce feeding in ovariectomized rats. Physiol. Behav. 77, 233–241.

Ivanova, T., Mendez, P., Garcia-Segura, L.M., Beyer, C., 2002. Rapid stimulation of the PI3-kinase/Akt signaling pathway in developing midbrain neurones by oestrogen. J. Neuroendocrinol. 14, 73–79.

Kahn, B.B., Flier, J.S., 2000. Obesity and insulin resistance. J. Clin. Invest. 106, 473–481.

Kalaitzidis, D., Gilmore, T.D., 2005. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol. Metab. 16, 46–52.

Kannel, W.B., Cupples, L.A., Ramaswami, R., Stokes, J., Kreger, B.E., Higgins, M., 1991. Regional obesity and risk of cardiovascular disease; the Framingham study. J. Clin. Epidemiol. 44, 183–190.

Kelly, M.J., Levin, E.R., 2001. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab. 12, 152–156.

Kemnitz, J.W., Gibber, J.R., Lindsay, K.A., Eisele, S.G., 1989. Effects of ovarian hormones on eating behaviors, body weight, and glucoregulation in rhesus monkeys. Horm. Behav. 23, 235–250.

Korner, J., Chua Jr., S.C., Williams, J.A., Leibel, R.L., Wardlaw, S.L., 1999. Regulation of hypothalamic proopiomelanocortin by leptin in lean and obese rats. Neuroendocrinology 70, 377–383.

Krotkiewski, M., Bjorntorp, P., Sjostrom, L.,Smith, U., 1983. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J. Clin. Invest. 72, 1150–1162.

Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., Gustafsson, J.A., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93, 5925–5930.

Ladyman, S.R., Grattan, D.R., 2005. Suppression of leptin receptor messenger ribonucleic acid and leptin responsiveness in the ventromedial nucleus of the hypothalamus during pregnancy in the rat. Endocrinology 146, 3868–3874.

Lee, C.G., Carr, M.C., Murdoch, S.J., Mitchell, E., Woods, N.F., Wener, M.H., Chandler, W.L., Boyko, E.J., Brunzell, J.D., 2009. Adipokines, inflammation, and visceral adiposity

across the menopausal transition: a prospective study. J. Clin. Endocrinol. Metab. 94, 1104–1110.

Leshner, A.I., Collier, G., 1973. The effects of gonadectomy on the sex differences in dietary self-selection patterns and carcass compositions of rats. Physiol. Behav. 11, 671–676.

Levin, B.E., 1999. Arcuate NPY neurons and energy homeostasis in diet-induced obese and resistant rats. Am. J. Physiol. 276, R382–R387.

Lindell, K., Bennett, P.A., Itoh, Y., Robinson, I.C., Carlsson, L.M., Carlsson, B., 2001. Leptin receptor 5′ untranslated regions in the rat: relative abundance, genomic organization and relation to putative response elements. Mol. Cell. Endocrinol. 172, 37–45.

Louis-Sylvestre, J., Larue-Achagiotis, C., Le Magnen, J., 1980. Oral induction of the insulin hyper-responsiveness in rats with ventromedial hypothalamic lesions. Horm. Metab. Res. 12, 671–676.

Lu, S.F., McKenna, S.E., Cologer-Clifford, A., Nau, E.A., Simon, N.G., 1998. Androgen receptor in mouse brain: sex differences and similarities in autoregulation. Endocrinology 139, 1594–1601.

Machinal, F., Dieudonne, M.N., Leneveu, M.C., Pecquery, R., Giudicelli, Y., 1999. In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes: evidence for a regional specific regulation by sex steroid hormones. Endocrinology 140, 1567–1574.

MacLusky, N.J., Walters, M.J., Clark, A.S., Toran-Allerand, C.D., 1994. Aromatase in the cerebral cortex, hippocampus, and mid-brain: ontogeny and developmental implications. Mol. Cell. Neurosci. 5, 691–698.

Malyala, A., Zhang, C., Bryant, D.N., Kelly, M.J., Ronnekleiv, O.K., 2008. PI3K signaling effects in hypothalamic neurons mediated by estrogen. J. Comp. Neurol. 506, 895–911.

Merchenthaler, I., Lane, M.V., Numan, S., Dellovade, T.L., 2004. Distribution of estrogen receptor alpha and beta in the mouse central nervous system: in vivo autoradiographic and immunocytochemical analyses. J. Comp. Neurol. 473, 270–291.

Milam, K.M., Stern, J.S., Storlien, L.H., Keesey, R.E., 1980. Effect of lateral hypothalamic lesions on regulation of body weight and adiposity in rats. Am. J. Physiol. 239, R337–R343.

Mitra, S.W., Hoskin, E., Yudkovitz, J., Pear, L., Wilkinson, H.A., Hayashi, S., Pfaff, D.W., Ogawa, S., Rohrer, S.P., Schaeffer, J.M., McEwen, B.S., Alves, S.E., 2003. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 144, 2055–2067.

Morton,G.J., Niswender, K.D., Rhodes, C.J.,Myers Jr., M.G., Blevins, J.E., Baskin, D.G., Schwartz, M.W., 2003. Arcuate nucleus-specific leptin receptor gene therapy attenuates the obesity phenotype of Koletsky (fa(k)/fa(k)) rats. Endocrinology 144, 2016–2024.

Mueller, K., Hsiao, S., 1980. Estrus- and ovariectomy-induced body weight changes: evidence for two estrogenic mechanisms. J. Comp. Physiol. Psychol. 94, 1126–1134.

Musatov, S., Chen, W., Pfaff, D.W., Mobbs, C.V., Yang, X.J., Clegg, D.J., Kaplitt, M.G., Ogawa, S., 2007. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc.Natl. Acad. Sci.U. S.A. 104, 2501–2506.

Obici, S., 2009. Minireview: Molecular targets for obesity therapy in the brain. Endocrinology 150, 2512–2517.

Ohlsson, C., Hellberg, N., Parini, P., Vidal, O., Bohlooly, M., Rudling, M., Lindberg, M.K., Warner, M., Angelin, B., Gustafsson, J.A., 2000. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha- deficient male mice. Biochem. Biophys. Res. Commun. 278, 640–645.

Okura, T., Koda, M., Ando, F., Niino, N., Ohta, S., Shimokata, H., 2003a. Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution. Int. J. Obes. Relat. Metab. Disord. 27, 1020–1027.

Okura, T., Koda, M., Ando, F., Niino, N., Tanaka, M., Shimokata, H., 2003b. Association of the mitochondrial DNA 15497G/A polymorphism with obesity in a middle-aged and elderly Japanese population. Hum. Genet. 113, 432–436.

Olofsson, L.E., Pierce, A.A., Xu, A.W., 2009. Functional requirement of AgRP and NPY neurons in ovarian cycle-dependent regulation of food intake. Proc. Natl. Acad. Sci. U. S. A. 106, 15932–15937.

Osterlund, M., Kuiper, G.G., Gustafsson, J.A., Hurd, Y.L., 1998. Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res. Mol. Brain Res. 54, 175–180.

Pappas, T.C., Gametchu, B., Watson, C.S., 1995. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 9, 404–410.

Payette, C., Blackburn, P., Lamarche, B., Tremblay, A., Bergeron, J., Lemieux, I., Despres, J.P., Couillard, C., 2009. Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations. Metabolism 58, 1593–1601.

Pelletier, G., Li, S., Luu-The, V., Labrie, F., 2007. Oestrogenic regulation of pro-opiomelanocortin, neuropeptide Y and corticotrophin-releasing hormone mRNAs in mouse hypothalamus. J. Neuroendocrinol. 19, 426–431.

Pierroz, D.D., Ziotopoulou, M., Ungsunan, L., Moschos, S., Flier, J.S., Mantzoros, C.S., 2002. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 51, 1337−1345.

Poehlman, E.T., Toth, M.J., Gardner, A.W., 1995. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann. Intern. Med. 123, 673−675.

Pozzi, S., Benedusi, V., Maggi, A., Vegeto, E., 2006. Estrogen action in neuroprotection and brain inflammation. Ann. N. Y. Acad. Sci. 1089, 302−323.

Qiu, J., Bosch, M.A., Tobias, S.C., Grandy, D.K., Scanlan, T.S., Ronnekleiv, O.K., Kelly, M.J., 2003. Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J. Neurosci. 23, 9529−9540.

Razandi, M., Pedram, A., Greene, G.L., Levin, E.R., 1999. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13, 307−319.

Rowland, N., Meile, M.J., Nicolaidis, S., 1975. Metering of intravenously infused nutrients in VMH lesioned rats. Physiol. Behav. 15, 443−448.

Ryan, A.S., Nicklas, B.J., Berman, D.M., 2002. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25, 127−133.

Samaras, K., Hayward, C.S., Sullivan, D., Kelly, R.P., Campbell, L.V., 1999. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care 22, 1401−1407.

Schwartz, M.W., Porte Jr., D., 2005. Diabetes, obesity, and the brain. Science 307, 375−379.

Schwartz, M.W., Woods, S.C., Porte, D.J., Seeley, R.J., Baskin, D.G., 2000. Central nervous system control of food intake. Nature 404, 661−671.

Seeley, R.J., Woods, S.C., 2003. Monitoring of stored and available fuel by the CNS: implications for obesity. Nat. Rev. Neurosci. 4, 901−909.

Seeley, R.J., vanDijk, G.,Campfield, L.A.,Smith, F.J., Burn, P.,Nelligan, J.A., Bell, S.M., Baskin, D.G.,Woods, S.C., Schwartz, M.W., 1996. Intraventricular leptin reduces food intake and body weight of lean rats but not obese Zucker rats. Horm. Metab. Res. 28, 664−668.

Seeley, R., Yagaloff, K., Fisher, S., Burn, P., Thiele, T., van, D.G., Baskin, D., Schwartz, M., 1997. Melanocortin receptors in leptin effects. Nature 390, 349.

Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., Flier, J.S., 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015–3025.

Shima, N., Yamaguchi, Y., Yuri, K., 2003. Distribution of estrogen receptor beta mRNA-containing cells in ovariectomized and estrogen-treated female rat brain. Anat. Sci. Int. 78, 85–97.

Shimizu, H., Shimomura, Y., Nakanishi, Y., Futawatari, T., Ohtani, K., Sato, N., Mori, M., 1997. Estrogen increases in vivo leptin production in rats and human subjects. J. Endocrinol. 154, 285–292.

Shoelson, S.E., Herrero, L., Naaz, A., 2007. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169–2180.

Shughrue, P., Scrimo, P., Lane, M., Askew, R., Merchenthaler, I., 1997a. The distribution of estrogen receptor-beta mRNA in forebrain regions of the estrogen receptor-alpha knockout mouse. Endocrinology 138, 5649–5652.

Shughrue, P.J., Lane, M.V., Merchenthaler, I., 1997b. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J. Comp. Neurol. 388, 507–525.

Shughrue, P.J., Lubahn, D.B., Negro-Vilar, A., Korach, K.S., Merchenthaler, I., 1997c. Responses in the brain of estrogen receptor alpha-disrupted mice. Proc. Natl. Acad. Sci. U. S. A. 94, 11008–11012.

Simerly, R.B., Chang, C.,Muramatsu,M., Swanson, L.W., 1990. Distribution of androgen and estrogen receptormRNA-containing cells in the rat brain: an in situ hybridization study. J. Comp. Neurol. 294, 76–95.

Simoncini, T.,Hafezi-Moghadam, A., Brazil,D.P., Ley, K., Chin,W.W., Liao, J.K., 2000. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538–541.

Simonian, S.X., Herbison, A.E., 1997. Differential expression of estrogen receptor alpha and beta immunoreactivity by oxytocin neurons of rat paraventricular nucleus. J. Neuroendocrinol. 9, 803–806.

Simonian, S.X., Spratt, D.P., Herbison, A.E., 1999. Identification and characterization of estrogen receptor alpha-containing neurons projecting to the vicinity of the gonadotropin-releasing hormone perikarya in the rostral preoptic area of the rat. J. Comp. Neurol. 411, 346–358.

Singh, M., 2001. Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. Endocrine 14, 407–415.

Slamberova, R., Hnatczuk, O.C., Vathy, I., 2004. Expression of proopiomelanocortin and proenkephalin mRNA in sexually dimorphic brain regions are altered in adult male and female rats treated prenatally with morphine. J. Pept. Res. 63, 399–408.

Speer, G., Cseh, K., Fuszek, P., Dworak, O., Vargha, P., Takacs, I., Nagy, Z., Lakatos, P., 2001. The role of estrogen receptor, vitamin D receptor and calcium receptor genotypes in the pathogenesis of colorectal cancer. Orv. Hetil. 142, 947–951.

Stein, B., Yang, M.X., 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol. 15, 4971–4979.

Steinbaum, S.R., 2004. Themetabolic syndrome: an emerging health epidemic in women. Prog. Cardiovasc. Disord. 46, 321–326.

Sutter-Dub, M.T., 2002. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 67, 77–93.

Tartaglia, L.A., Dembski,M.,Weng, X., Deng,N., Culpepper, J., Devos, R., Richards, G.J., Campfield, L.A., Clark, F.T., Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, K.J., Smutko, J.S., Mays, G.G., Woolf, E.A., Monroe, C.A., Tepper, R.I., 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263–1271.

Thammacharoen, S., Lutz, T.A., Geary, N., Asarian, L., 2008. Hindbrain administration of estradiol inhibits feeding and activates estrogen receptor-alpha-expressing cells in the nucleus tractus solitarius of ovariectomized rats Endocrinology 149, 1609–1617.

Thornton, J.E., Cheung, C.C., Clifton, D.K., Steiner, R.A., 1997. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 138, 5063–5067.

Toran-Allerand, C.D., 2005. Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol. Ann. N. Y. Acad. Sci. 1052, 136–144.

Toran-Allerand, C.D., Tinnikov, A.A., Singh, R.J., Nethrapalli, I.S., 2005. 17alpha-estradiol: a brain-active estrogen? Endocrinology 146, 3843–3850.

Turgeon, J.L., Carr, M.C., Maki, P.M., Mendelsohn, M.E., Wise, P.M., 2006. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr. Rev. 27, 575–605.

Van Dijk, G., Thiele, T.E., Donahey, J.C., Campfield, L.A., Smith, F.J., Burn, P., Bernstein, I.L., Woods, S.C., Seeley, R.J., 1996. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FOS in the rat brain. Am. J. Physiol. 271, R1096–R1100.

Vasudevan, N., Pfaff, D.W., 2008. Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front. Neuroendocrinol. 29, 238–257.

Vegeto, E., Bonincontro, C., Pollio, G., Sala, A., Viappiani, S., Nardi, F., Brusadelli, A., Viviani, B., Ciana, P., Maggi, A., 2001. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J. Neurosci. 21, 1809–1818.

Vegeto, E., Belcredito, S., Etteri, S., Ghisletti, S., Brusadelli, A., Meda, C., Krust, A., Dupont, S., Ciana, P., Chambon, P., Maggi, A., 2003. Estrogen receptor-alpha mediates the brain anti-inflammatory activity of estradiol. Proc. Natl. Acad. Sci. U. S. A. 100, 9614–9619.

Vidal, O., Lindberg, M.K., Hollberg, K., Baylink, D.J., Andersson, G., Lubahn, D.B., Mohan, S., Gustafsson, J.A., Ohlsson, C., 2000. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. U. S. A. 97, 5474–5479.

Voisin, D.L., Simonian, S.X., Herbison, A.E., 1997. Identification of estrogen receptor-containing neurons projecting to the rat supraoptic nucleus. Neuroscience 78, 215–228.

Wade, G.N., 1972. Gonadal hormones and behavioral regulation of body weight. Physiol. Behav. 8, 523–534.

Wade, G.N., Gray, J.M., 1979. Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol. Behav. 22, 583–593.

Wade, G.N., Zucker, I., 1970. Modulation of food intake and locomotor activity in female rats by diencephalic hormone implants. J. Comp. Physiol. Psychol. 72, 328–336.

Wade, G.N., Gray, J.M., Bartness, T.J., 1985. Gonadal influences on adiposity. Int. J. Obes. 9 (Suppl 1), 83–92.

Wallen, W.J., Belanger, M.P., Wittnich, C., 2001. Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J. Nutr. 131, 2351–2357.

Wang, P., Mariman, E., Renes, J., Keijer, J., 2008a. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell. Physiol. 216, 3–13.

Wang, Y., Beydoun, M.A., Liang, L., Caballero, B., Kumanyika, S.K., 2008b. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 16, 2323–2330.

Wellen, K.E., Hotamisligil, G.S., 2003. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785–1788.

Wellen, K.E., Hotamisligil, G.S., 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111−1119.

Wilkinson, H.A., Dahllund, J., Liu, H., Yudkovitz, J., Cai, S.J., Nilsson, S., Schaeffer, J.M., Mitra, S.W., 2002. Identification and characterization of a functionally distinct form of human estrogen receptor beta. Endocrinology 143, 1558−1561.

Williams, G., Bing, C., Cai, X.J., Harrold, J.A., King, P.J., Liu, X.H., 2001. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol. Behav. 74, 683−701.

Wilson, M.E., Liu, Y., Wise, P.M., 2002. Estradiol enhances Akt activation in cortical explant cultures following neuronal injury. Brain Res. Mol. Brain Res. 102, 48−54.

Wise, P.M., Scarbrough, K., Weiland, N.G., Larson, G.H., 1990. Diurnal pattern of proopiomelanocortin gene expression in the arcuate nucleus of proestrous, ovariectomized, and steroid-treated rats: a possible role in cyclic luteinizing hormone secretion. Mol. Endocrinol. 4, 886−892.

Wise, P.M., Suzuki, S., Brown, C.M., 2009. Estradiol: a hormone with diverse and contradictory neuroprotective actions. Dialogues Clin. Neurosci. 11, 297−303.

Woods, S.C., Seeley, R.J., 2000. Adiposity signals and the control of energy homeostasis. Nutrition 16, 894−902.

Woods, S.C., Schwartz, M.W., Baskin, D.G., Seeley, R.J., 2000. Food intake and the regulation of body weight. Annu. Rev. Psychol. 51, 255−277.

Wu-Peng, S., Rosenbaum, M., Nicolson, M., Chua, S.C., Leibel, R.L., 1999. Effects of exogenous gonadal steroids on leptin homeostasis in rats. Obes. Res. 7, 586−592.

Yamada, Y., Ando, F., Niino, N., Ohta, S., Shimokata, H., 2002. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density of the femoral neck in elderly Japanese women. J. Mol. Med. 80, 452−460.

York, D., Bray, G., 1972. Dependence of hypothalamic obesity on insulin, the pituitary and the adrenal gland. Endocrinology 90, 885−894.

Yu, I.C., Lin, H.Y., Liu, N.C., Wang, R.S., Sparks, J.D., Yeh, S., Chang, C., 2008. Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology 149, 2361−2368.

Zhang, Y., Proenca, R.,Maffei, M., Barone, M., Leopold, L., Friedman, J.M., 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425−432.